Home » Aastrom Receives FDA Fast Track Designation for Phase 3 CLI Program
Aastrom Receives FDA Fast Track Designation for Phase 3 CLI Program
Astrom Biosciences, Inc. Monday announced that the FDA has granted fast track designation for the company’s critical limb ischemia cell therapy development program.
MarketWatch
MarketWatch
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May